These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29386432)

  • 1. [Adverse Effect Predictions Based on Computational Toxicology Techniques and Large-scale Databases].
    Uesawa Y
    Yakugaku Zasshi; 2018; 138(2):185-190. PubMed ID: 29386432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The principle of safety evaluation in medicinal drug - how can toxicology contribute to drug discovery and development as a multidisciplinary science?
    Horii I
    J Toxicol Sci; 2016; 41(Special):SP49-SP67. PubMed ID: 28250284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities.
    Ursem CJ; Kruhlak NL; Contrera JF; MacLaughlin PM; Benz RD; Matthews EJ
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):1-22. PubMed ID: 19422096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities.
    Matthews EJ; Ursem CJ; Kruhlak NL; Benz RD; Sabaté DA; Yang C; Klopman G; Contrera JF
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):23-42. PubMed ID: 19422098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data quality in predictive toxicology: identification of chemical structures and calculation of chemical properties.
    Helma C; Kramer S; Pfahringer B; Gottmann E
    Environ Health Perspect; 2000 Nov; 108(11):1029-33. PubMed ID: 11102292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational toxicology: Its essential role in reducing drug attrition.
    Naven RT; Louise-May S
    Hum Exp Toxicol; 2015 Dec; 34(12):1304-9. PubMed ID: 26614820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicological and clinical computational analysis and the US FDA/CDER.
    Benz RD
    Expert Opin Drug Metab Toxicol; 2007 Feb; 3(1):109-24. PubMed ID: 17269898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of Spontaneously Reported Adverse Events].
    Nakamura M
    Yakugaku Zasshi; 2016; 136(4):549-56. PubMed ID: 27040337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The implementation of medical monitoring programs following potentially hazardous exposures: a medico-legal perspective.
    Vearrier D; Greenberg MI
    Clin Toxicol (Phila); 2017 Nov; 55(9):956-969. PubMed ID: 28644057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of toxicological information in drug design.
    Matthews EJ; Benz RD; Contrera JF
    J Mol Graph Model; 2000 Dec; 18(6):605-15. PubMed ID: 11155316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug voyager: a computational platform for exploring unintended drug action.
    Oh M; Ahn J; Lee T; Jang G; Park C; Yoon Y
    BMC Bioinformatics; 2017 Feb; 18(1):131. PubMed ID: 28241745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the associations between drug side-effects and therapeutic indications.
    Wang F; Zhang P; Cao N; Hu J; Sorrentino R
    J Biomed Inform; 2014 Oct; 51():15-23. PubMed ID: 24727480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicophore exploration as a screening technology for drug design and discovery: techniques, scope and limitations.
    Singh PK; Negi A; Gupta PK; Chauhan M; Kumar R
    Arch Toxicol; 2016 Aug; 90(8):1785-802. PubMed ID: 26341667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.
    Xu R; Wang Q
    J Biomed Inform; 2015 Jun; 55():64-72. PubMed ID: 25817969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic drug safety evaluation based on public genomic expression (Connectivity Map) data: myocardial and infectious adverse reactions as application cases.
    Wang K; Weng Z; Sun L; Sun J; Zhou SF; He L
    Biochem Biophys Res Commun; 2015 Feb; 457(3):249-55. PubMed ID: 25576362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Social Media Listening for Routine Post-Marketing Safety Surveillance.
    Powell GE; Seifert HA; Reblin T; Burstein PJ; Blowers J; Menius JA; Painter JL; Thomas M; Pierce CE; Rodriguez HW; Brownstein JS; Freifeld CC; Bell HG; Dasgupta N
    Drug Saf; 2016 May; 39(5):443-54. PubMed ID: 26798054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai.
    Du W; Levine M; Wang L; Zhang Y; Yi C; Wang H; Wang X; Xie H; Xu J; Jin H; Wang T; Huang G; Wu Y
    Can J Clin Pharmacol; 2007; 14(1):e40-4. PubMed ID: 17237524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.